Chemopreventive Agent Development

Designs, develops, implements, and monitors research on interventions that may block, reverse, or delay the early stages of cancer. Investigates nutrients, micronutrients, natural products, pharmacologic agents, biomolecules, and vaccines from preclinical to early-phase I clinical studies. Helps investigators to bridge the gaps between biology and identifying potential targets, and between discovery of targets and agents and clinical testing in people.

On This Page

All Headings will automatically be pulled in to this list.
Do not edit the content on this template.

Major Programs

Staff List

Grid View

Name, Email, Phone	Room	Group(s)/Office
Asefa, Wosene wosene.asefa@nih.gov 240-276-6422	5E504	Program Support Assistant \| Chemopreventive Agent Development
Biswas, Kajal, Ph.D. kajal.biswas2@nih.gov 240-276-5614	5E540	Program Officer \| Chemopreventive Agent Development
Boring, Daniel, R.Ph., Ph.D. [C] daniel.boring@nih.gov		Contractor \| Chemopreventive Agent Development
Cholewa, Brian, Ph.D. brian.cholewa@nih.gov 240-276-7545	5E446	Deputy Chief \| Chemopreventive Agent Development
Clifford, John, Ph.D. john.clifford@nih.gov 202-235-4482	5E430	Program Officer \| Chemopreventive Agent Development
Gunasekharan, Vignesh, Ph.D. vignesh.gunasekharan@nih.gov 240-276-5814	5E438	Program Officer \| Chemopreventive Agent Development
Mohammed, Altaf, Ph.D. altaf.mohammed@nih.gov 240-276-6082	5E542	Deputy Chief \| Chemopreventive Agent Development
Nalli, Ancy, Ph.D., M.S. ancy.nalli@nih.gov 202-276-5265	5E536	Program Officer \| Chemopreventive Agent Development
Sei, Shizuko, M.D. shizuko.sei@nih.gov 240-276-5005	5E452	Co-Chief \| Chemopreventive Agent Development
Shoemaker, Robert, Ph.D. robert.shoemaker@nih.gov 240-276-7077	5E454	Co-Chief \| Chemopreventive Agent Development Acting Chief \| Nutritional Science
Vlad, Anda, M.D., Ph.D. anda.vlad@nih.gov 240-276-6422	5E538	Program Officer \| Chemopreventive Agent Development

Grants

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Siskind, Leah J	University Of Louisville United States	Protecting the kidney from cisplatin induced injury and progression to chronic kidney disease	1R01CA305985-01	Marjorie Perloff, M.D.
Sorror, Mohamed	Fred Hutchinson Cancer Center United States	Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality	5R01CA227092-06	Marjorie Perloff, M.D.
Tennis, Meredith A	University Of Colorado Denver United States	Modeling lung squamous cell carcinoma premalignancy and prevention	1R01CA298925-01
Thangaraju, Muthusamy	Augusta University United States	Bacteria-derived xenobiotics in colon cancer prevention: Link to GPR109A and colonic ketogenesis	5R01CA275840-03
Valdimarsdottir, Heiddis	Icahn School Of Medicine At Mount Sinai United States	Systematic Light Exposure Effects on Circadian Rhythms Entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation	5R01CA260961-04	Marjorie Perloff, M.D.
Yaddanapudi, Kavitha	University Of Louisville United States	A Stem Cell Based Exosomal Vaccine for the Prevention of Cancer	5R21CA277314-02
You, Ming	Methodist Hospital Research Institute United States	Chemoprevention of lung cancer by targeting lonidamine to mitochondria	5R01CA232433-05	John Clifford, Ph.D.
Yu, Dihua	University Of Tx Md Anderson Can Ctr United States	Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer	5R01CA270010-03	Marjorie Perloff, M.D.
Zi, Xiaolin	University Of California-Irvine United States	Nautral products for targeting Skp2 in cancer interception	5UG3CA290368-02	Altaf Mohammed, Ph.D.